Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cipla
QuintilesIMS
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
US Army
Fuji
Daiichi Sankyo
Federal Trade Commission

Generated: October 18, 2017

DrugPatentWatch Database Preview

TOPAMAX SPRINKLE Drug Profile

« Back to Dashboard

What is the patent landscape for Topamax Sprinkle, and what generic Topamax Sprinkle alternatives are available?

Topamax Sprinkle is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-nine patent family members in thirty-one countries and one supplementary protection certificate in one country.

The generic ingredient in TOPAMAX SPRINKLE is topiramate. There are twenty-six drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the topiramate profile page.

Summary for Tradename: TOPAMAX SPRINKLE

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list52
Clinical Trials: see list53
Patent Applications: see list5,803
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TOPAMAX SPRINKLE at DailyMed

Pharmacology for Tradename: TOPAMAX SPRINKLE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
TOPAMAX SPRINKLE
topiramate
CAPSULE;ORAL020844-003Oct 26, 1998DISCNNoNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
TOPAMAX SPRINKLE
topiramate
CAPSULE;ORAL020844-003Oct 26, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TOPAMAX SPRINKLE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
TOPAMAX SPRINKLE
topiramate
CAPSULE;ORAL020844-003Oct 26, 1998► Subscribe► Subscribe
Janssen Pharms
TOPAMAX SPRINKLE
topiramate
CAPSULE;ORAL020844-003Oct 26, 1998► Subscribe► Subscribe
Janssen Pharms
TOPAMAX SPRINKLE
topiramate
CAPSULE;ORAL020844-003Oct 26, 1998► Subscribe► Subscribe
Janssen Pharms
TOPAMAX SPRINKLE
topiramate
CAPSULE;ORAL020844-003Oct 26, 1998► Subscribe► Subscribe
Janssen Pharms
TOPAMAX SPRINKLE
topiramate
CAPSULE;ORAL020844-003Oct 26, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for TOPAMAX SPRINKLE

Drugname Dosage Strength RLD Submissiondate
topiramateCapsules15 mg and 25 mgTopamax Sprinkle9/7/2005

Non-Orange Book Patents for Tradename: TOPAMAX SPRINKLE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,696,091 Pharmaceutical composition of topiramate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TOPAMAX SPRINKLE

Country Document Number Estimated Expiration
Australia763643► Subscribe
Indonesia26982► Subscribe
Israel138032► Subscribe
Hong Kong1032009► Subscribe
Australia2798999► Subscribe
European Patent Office1066027► Subscribe
Slovakia285440► Subscribe
Estonia200000503► Subscribe
Canada2322644► Subscribe
Poland194559► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TOPAMAX SPRINKLE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB95/028United Kingdom► SubscribePRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Fish and Richardson
McKinsey
Dow
Colorcon
AstraZeneca
Teva
Cipla
Baxter
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot